logo

For the Inventor, By the Inventor

Los Angeles, CA, United States of America

Marc D Better

This inventor holds 29 USPTO granted patents, primarily in Recombinant Proteins. Top assignees: Xoma Corporation, Xoma Technology Ltd., Research Development Foundation. Active years: 1994-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc D Better. Retrieved from https://idiyas.com/inventor/marc-d-better

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29

% Patents Active = 89.7

Average Co-Inventor Count = 2.7

ph-index = 15

Forward Citations = 1,459(Granted Patents)


Location History:

  • Oakland, CA (US) (2004)
  • Los Angeles, CA (US) (1994 - 2010)

Company Filing History:

goldMedal20 out of 142 
 
Xoma Corporation
 patents
silverMedal7 out of 84 
 
Xoma Technology Ltd.
 patents
bronzeMedal1 out of 299 
 
Research Development Foundation
 patents
4. 1 out of 20 
 
Xoma (US) LLC
 patents

Years Active: 1994-2010

Loading Chart...
Areas of Expertise:
Recombinant Peptide Production
Immunotoxins
Ribosome-Inactivating Proteins
Chimeric Antibodies
Fusion Proteins
Inducible Promoter
Modular Assembly
Antibody Genes
Polynucleotides
Microbial Production
Gelonin Sequences
Pectate Lyase
29 patents (USPTO):Explore Patents
1. 7749731 - Methods for recombinant peptide production (2010-07-06),
2. 7247454 - Methods for recombinant peptide production (2007-07-24),
3. 7153932 - Immunotoxins comprising ribosome-inactivating proteins (2006-12-26),
4. 6803210 - Methods and cells for expression of recombinant protein products under the transcriptional control of an inducible promoter (2004-10-12),
5. 6649742 - Immunotoxins comprising ribosome-inactivating proteins (2003-11-18),
6. 6500648 - Methods for recombinant peptide production (2002-12-31),
7. 6461824 - Production of chimeric antibodies with specificity to human tumor antigens (2002-10-08),
8. 6376217 - Fusion proteins and polynucleotides encoding gelonin sequences (2002-04-23),
9. 6274344 - Methods for recombinant microbial production of fusion proteins and BPI-derived peptides (2001-08-14),
10. 6242219 - Methods for recombinant peptide production (2001-06-05),
11. 6204023 - Modular assembly of antibody genes, antibodies prepared thereby and use (2001-03-20),
12. 6146850 - Proteins encoding gelonin sequences (2000-11-14),
13. 6146631 - Immunotoxins comprising ribosome-inactivating proteins (2000-11-14),
14. 5851802 - Methods for recombinant microbial production of fusion proteins and (1998-12-22),
15. 5846818 - Pectate lyase signal sequence (1998-12-08),

Title: Innovator Spotlight: Marc D. Better and His Contributions to Biotechnology

Introduction: Marc D. Better, based in Los Angeles, CA, is a prominent inventor with an impressive portfolio of 29 patents to his name. His groundbreaking work primarily focuses on the biotechnological field, particularly in recombinant peptide production.

Latest Patents: Among his latest innovations are methods for recombinant peptide production. These patents provide enhanced techniques for producing recombinant peptides efficiently from bacterial cells, signifying a major advancement in the biotechnology sector.

Career Highlights: Marc has made significant contributions to the field during his tenure at Xoma Corporation and Xoma Technology Ltd. His expertise in biopharmaceutical development has propelled innovations that enhance the therapeutic potential of recombinant proteins.

Collaborations: Throughout his career, Marc has collaborated with esteemed colleagues, including Shau-Ping Lei and Randy R. Robinson. These collaborations reflect his commitment to advancing scientific research through teamwork and shared knowledge.

Conclusion: Marc D. Better stands as a key figure in the biotechnology industry, with a notable number of patents and significant contributions to recombinant peptide production. His work continues to influence the development of new therapies, paving the way for future innovations in this vital field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…